{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:59:56Z","timestamp":1772135996102,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Samjin Pharmaceutical","award":["0620201110"],"award-info":[{"award-number":["0620201110"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OXC. We obtained 711 OXC samples from 618 patients with epilepsy who were enrolled in the Epilepsy Registry Cohort of Seoul National University Hospital from February 2011 to January 2014. The plasma PK model was developed using a nonlinear mixed-effect modelling method with NONMEM (ver 7.3). A one-compartment model with a first-order absorption model and proportional residual error adequately described the MHD concentration\u2013time profiles. The only covariate incorporated for CL\/F and V\/F was body weight. Of the 447 patients analysed, 28 (6.26%) had dose-related adverse events (DRAEs), which were dizziness, somnolence, headache, and diplopia. For DRAE occurrence, the cut-off values of the MHD trough and AUC were 12.27\u00a0mg\/L (specificity 0.570, sensitivity 0.643) and 698.5\u00a0mg h\/L (specificity, sensitivity 0.571), respectively. Multivariate analysis showed the sole dizziness symptom was significantly associated with both the MHD trough and the AUC (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.013,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.038, respectively). We newly developed a population PK model using sparse sampling data from patients with epilepsy, and the model better reflects the actual clinical situation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-85920-0","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T12:47:41Z","timestamp":1616071661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy"],"prefix":"10.1038","volume":"11","author":[{"given":"Yoonhyuk","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonghae","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kon","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"85920_CR1","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1212\/WNL.54.12.2237","volume":"54","author":"TA Glauser","year":"2000","unstructured":"Glauser, T. A. et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 54, 2237. https:\/\/doi.org\/10.1212\/WNL.54.12.2237 (2000).","journal-title":"Neurology"},{"key":"85920_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1212\/wnl.52.4.732","volume":"52","author":"SC Schachter","year":"1999","unstructured":"Schachter, S. C. et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 52, 732\u2013737. https:\/\/doi.org\/10.1212\/wnl.52.4.732 (1999).","journal-title":"Neurology"},{"key":"85920_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/seiz.2000.0391","volume":"9","author":"S Shorvon","year":"2000","unstructured":"Shorvon, S. Oxcarbazepine: a review. Seizure 9, 75\u201379. https:\/\/doi.org\/10.1053\/seiz.2000.0391 (2000).","journal-title":"Seizure"},{"key":"85920_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3109\/00498258609043567","volume":"16","author":"H Sch\u00fctz","year":"1986","unstructured":"Sch\u00fctz, H., Feldmann, K. F., Faigle, J. W., Kriemler, H. P. & Winkler, T. The metabolism of 14C-oxcarbazepine in man. Xenobiotica 16, 769\u2013778. https:\/\/doi.org\/10.3109\/00498258609043567 (1986).","journal-title":"Xenobiotica"},{"key":"85920_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","volume":"24","author":"G Flesch","year":"2004","unstructured":"Flesch, G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin. Drug. Investig. 24, 185\u2013203. https:\/\/doi.org\/10.2165\/00044011-200424040-00001 (2004).","journal-title":"Clin. Drug. Investig."},{"key":"85920_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","volume":"42","author":"TW May","year":"2003","unstructured":"May, T. W., Korn-Merker, E. & Rambeck, B. Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokinet. 42, 1023\u20131042. https:\/\/doi.org\/10.2165\/00003088-200342120-00002 (2003).","journal-title":"Clin. Pharmacokinet."},{"key":"85920_CR7","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/j.1528-1167.2011.03318.x","volume":"53","author":"DW Kim","year":"2012","unstructured":"Kim, D. W. et al. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. Epilepsia 53, e9-12. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03318.x (2012).","journal-title":"Epilepsia"},{"key":"85920_CR8","unstructured":"Trileptal (oxcarbazepine) [package insert]. East Hanover, NJ. Novartis Pharmaceutical Corp.;2000."},{"key":"85920_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1592\/phco.21.11.904.34513","volume":"21","author":"TA Glauser","year":"2001","unstructured":"Glauser, T. A. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 21, 904\u2013919. https:\/\/doi.org\/10.1592\/phco.21.11.904.34513 (2001).","journal-title":"Pharmacotherapy"},{"key":"85920_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/aps.2014.76","volume":"35","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol. Sin. 35, 1342\u20131350. https:\/\/doi.org\/10.1038\/aps.2014.76 (2014).","journal-title":"Acta Pharmacol. Sin."},{"key":"85920_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.seizure.2013.11.015","volume":"23","author":"YS Kim","year":"2014","unstructured":"Kim, Y. S. et al. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure 23, 208\u2013212. https:\/\/doi.org\/10.1016\/j.seizure.2013.11.015 (2014).","journal-title":"Seizure"},{"key":"85920_CR12","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1111\/epi.13566PMID-27666425","volume":"57","author":"J Moon","year":"2016","unstructured":"Moon, J. et al. HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption. Epilepsia 57, 1879\u20131886. https:\/\/doi.org\/10.1111\/epi.13566PMID-27666425 (2016).","journal-title":"Epilepsia"},{"key":"85920_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.seizure.2015.07.018","volume":"31","author":"A Sattler","year":"2015","unstructured":"Sattler, A., Schaefer, M. & May, T. W. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy. Seizure 31, 149\u2013154. https:\/\/doi.org\/10.1016\/j.seizure.2015.07.018 (2015).","journal-title":"Seizure"},{"key":"85920_CR14","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/01.wnl.0000188819.45330.90","volume":"65","author":"X Dong","year":"2005","unstructured":"Dong, X., Leppik, I. E., White, J. & Rarick, J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 65, 1976\u20131978. https:\/\/doi.org\/10.1212\/01.wnl.0000188819.45330.90 (2005).","journal-title":"Neurology"},{"key":"85920_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson, B. J. & Holford, N. H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303\u2013332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708 (2008).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"85920_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson, B. J. & Holford, N. H. G. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24, 25\u201336. https:\/\/doi.org\/10.2133\/dmpk.24.25 (2009).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"85920_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11598930-000000000-00000","volume":"51","author":"SC McLeay","year":"2012","unstructured":"McLeay, S. C., Morrish, G. A., Kirkpatrick, C. M. & Green, B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin. Pharmacokinet. 51, 319\u2013330. https:\/\/doi.org\/10.2165\/11598930-000000000-00000 (2012).","journal-title":"Clin. Pharmacokinet."},{"key":"85920_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.11613\/BM.2016.034","volume":"26","author":"F Habibzadeh","year":"2016","unstructured":"Habibzadeh, F., Habibzadeh, P. & Yadollahie, M. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem. Med. (Zagreb) 26, 297\u2013307. https:\/\/doi.org\/10.11613\/BM.2016.034 (2016).","journal-title":"Biochem. Med. (Zagreb)"},{"key":"85920_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/WNF.0b013e31824150a5","volume":"35","author":"KJ Park","year":"2012","unstructured":"Park, K. J. et al. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. Clin. Neuropharmacol. 35, 40\u201344. https:\/\/doi.org\/10.1097\/WNF.0b013e31824150a5 (2012).","journal-title":"Clin. Neuropharmacol."},{"key":"85920_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.5414\/cp202078","volume":"52","author":"J Peng","year":"2014","unstructured":"Peng, J., Zhang, H. N., Liu, Z. S., Xu, H. & Wang, Y. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. Int. J. Clin. Pharmacol. Ther. 52, 684\u2013692. https:\/\/doi.org\/10.5414\/cp202078 (2014).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"85920_CR21","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/j.ejps.2017.05.034","volume":"109s","author":"NJ Antunes","year":"2017","unstructured":"Antunes, N. J. et al. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Eur. J. Pharm. Sci. 109s, S116\u2013S123. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.034 (2017).","journal-title":"Eur. J. Pharm. Sci."},{"key":"85920_CR22","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1111\/bcp.13392","volume":"83","author":"C Rodrigues","year":"2017","unstructured":"Rodrigues, C. et al. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. Br. J. Clin. Pharmacol. 83, 2695\u20132708. https:\/\/doi.org\/10.1111\/bcp.13392 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"85920_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CPAA.S256972","volume":"12","author":"S Faison","year":"2020","unstructured":"Faison, S. et al. Predicted efficacy of once-daily extended-release oxcarbazepine (OxtellarXR(\u00ae)) monotherapy in adults and children with partial-onset seizures: exposure-response modeling and simulation. Clin. Pharmacol. 12, 135\u2013147. https:\/\/doi.org\/10.2147\/CPAA.S256972 (2020).","journal-title":"Clin. Pharmacol."},{"key":"85920_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1124\/dmd.109.030593","volume":"39","author":"G Flesch","year":"2011","unstructured":"Flesch, G., Czendlik, C., Renard, D. & Lloyd, P. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. Drug Metab. Dispos. 39, 1103. https:\/\/doi.org\/10.1124\/dmd.109.030593 (2011).","journal-title":"Drug Metab. Dispos."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85920-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85920-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85920-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:40:17Z","timestamp":1670028017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85920-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85920"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85920-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-138619\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"31 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6370"}}